drugset / Trial / NCT07182435
Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors
Phase 0
Not yet recruiting
36 enrolled
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 clinical study investigating RH125 as monotherapy or in combination therapy in patients with locally advanced or metastatic solid tumors who failed standard treatment, or were intolerant to standard treatment, or declined standard treatment. The aim of the study is to evaluate the tolerability, safety, immunogenicity, and preliminary efficacy of RH125 monotherapy or combination with PD-1 blocker.
Timeline
- Start
- 2025-09-15
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RH125 | Messenger RNA (mRNA) | 100 ug | — |
| Subject | RH125 | Messenger RNA (mRNA) | 150 ug | — |
| Subject | RH125 | Messenger RNA (mRNA) | 200 ug | — |
Indications
No indication recorded.